# DESCRIPTION

## STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

- disclose government sponsorship

## FIELD OF THE INVENTION

- relate to botulinum neurotoxin antibodies

## INTRODUCTION

- introduce botulism
- describe symptoms and treatment
- discuss botulinum neurotoxin serotypes
- highlight need for pharmaceutical agents
- mention existing vaccines and treatments
- discuss limitations of current treatments
- highlight importance of developing new treatments

## SUMMARY

- introduce neutralizing antibodies
- describe antibody binding to BoNT subtypes
- provide examples of antibodies
- describe antibody composition
- discuss VH and VL CDRs
- provide examples of VH and VL CDRs
- describe antibody formats
- discuss IgG antibodies
- provide examples of antibodies
- describe methods of inhibiting BoNT activity
- discuss compositions for neutralizing BoNT
- describe kits for neutralizing BoNT

## DEFINITIONS

- define BoNT polypeptide
- define BoNT serotype
- define BoNT subtype
- define anti-BoNT antibody
- define neutralization
- define potency
- define high affinity
- list abbreviations
- define polypeptide
- define antibody
- describe immunoglobulin polypeptides
- describe immunoglobulin light chains
- describe immunoglobulin heavy chains
- describe variable regions
- describe framework regions
- describe complementarity determining regions
- describe IMGTS system
- describe antibody structure
- describe light chains
- describe heavy chains
- describe immunoglobulin classes
- describe antibody fragments
- describe synthesis of antibody fragments
- define bispecific antibodies
- describe configurations of bispecific antibodies
- introduce production methods of bispecific antibodies
- define antigen-binding site
- describe structure of antigen-binding site
- define framework regions
- describe hypervariable regions
- define complementarily determining regions
- introduce 1B10 antibody
- describe other antibodies
- define immunological binding
- describe measurement of immunological binding
- define BoNT-neutralizing antibody
- describe properties of BoNT-neutralizing antibody
- introduce derivation of BoNT-neutralizing antibodies
- describe screening methods for BoNT-neutralizing antibodies
- define epitope
- describe properties of epitope
- define neutralizing epitope
- define isolated
- introduce single chain Fv polypeptide
- describe design of single chain Fv polypeptide
- define specifically binds to
- describe conservative substitution

## DETAILED DESCRIPTION

- introduce botulinum neurotoxin
- describe botulism disease
- motivate neutralizing antibodies
- describe antibody combinations
- introduce epitopes of botulinum neurotoxin
- describe neutralization of botulinum neurotoxin
- motivate treatment of botulism
- describe detection of botulism
- introduce epitopes specifically bound by botulinum neurotoxin antibodies
- describe potency of botulinum neurotoxin-neutralizing antibodies
- describe botulinum neurotoxin-neutralizing antibodies
- describe epitopes bound by antibodies

### I. Potency of Botulinum Neurotoxin (BoNT)-Neutralizing Antibodies.

- describe potency of botulinum neurotoxin-neutralizing antibodies

### II. Botulinum Neurotoxin (BoNT)-Neutralizing Antibodies.

- describe BoNT neutralizing antibodies
- introduce BoNT subtypes
- describe cross-reactive antibodies
- introduce epitopes of BoNT
- describe sequences of VH and VL domains
- describe relationship of antibodies
- motivate use of antibodies individually and in combination
- describe bispecific or polyspecific antibodies
- define CDRs of an antibody
- describe formation of single-chain Fv antibody
- describe binding affinity of anti-BoNT antibodies
- define epitopes bound by antibodies
- describe competitive inhibition of binding
- describe cross-reactivity of antibodies
- describe antibodies with same binding specificity

### III. Preparation of BoNT Neutralizing Antibodies.

- introduce recombinant expression of BoNT-neutralizing antibodies
- determine nucleic acid sequences encoding BoNT-neutralizing antibodies
- optimize codon preferences for expression systems
- synthesize nucleic acids using standard methods
- amplify and clone nucleic acids using molecular cloning techniques
- express gene in recombinantly engineered cells
- describe expression systems for expressing anti-BoNT antibodies
- require exposure to chaotropic agents for proper folding
- purify and renature expressed protein
- use secretion signal sequences for correctly-folded form
- transfect and express genes in mammalian cells
- culture cells used in the present disclosure
- describe techniques for using and manipulating antibodies
- subclone into expression vector pUC119mycHis
- add hexahistidine tag for purification
- describe preparation of whole polyclonal or monoclonal antibodies
- include individual, allelic, strain, or species variants
- select antibodies to bind one or more epitopes
- describe polyclonal antibody production
- immunize animals with immunogen and adjuvant
- monitor immune response and prepare antisera
- fractionate antisera to enrich for antibodies
- describe monoclonal antibody production
- inject animal with immunogen and sacrifice
- fuse spleen cells with myeloma cells
- screen hybridomas for individual clones
- immortalize cells using Epstein Barr Virus or oncogenes
- screen for production of antibodies with desired specificity
- enhance yield of monoclonal antibodies
- create recombinant DNA versions of antigen-binding regions
- use display systems and antibody production systems

### IV. Modification of BoNT Neutralizing Antibodies.

- introduce display techniques
- describe phage display
- explain antibody fragment gene insertion
- describe antigen affinity chromatography
- outline phage selection process
- discuss yeast display
- introduce chain shuffling
- describe light chain shuffling
- describe heavy chain shuffling
- outline scFv gene repertoire creation
- describe phage preparation and selection
- introduce site-directed mutagenesis
- describe CDR randomization
- outline affinity measurement
- describe CDR sequence combination
- introduce "doped" oligonucleotide synthesis
- describe PCR amplification
- outline phage antibody library creation
- describe affinity maturation using yeast display
- create anti-BoNT (scFv′)2 homodimers
- join scFv fragments through linker
- introduce cysteine residue by site-directed mutagenesis
- express scFv in pUC119
- purify scFv by IMAC
- reduce cysteine by incubation with beta-mercaptoethanol
- block scFv by addition of DTNB
- form (scFv′)2 dimer
- analyze by gel filtration
- determine affinity by BIAcore
- create anti-BoNT (scFv)2, Fab, and (Fab′)2 molecules
- express anti-BoNT scFv in E. coli
- purify scFv by IMAC
- create BoNT-neutralizing Fab
- express Fab in E. coli
- select neutralizing antibodies
- screen for specific binding to antigen
- select by immunochromatography
- select by surface plasmon resonance
- measure anti-BoNT antibody affinity
- determine KD and kinetics of binding

### V. Humanized, Human Engineered or Human Antibody Production.

- define humanized antibody
- describe chimeric antibodies
- motivate CDR-grafted antibodies
- summarize human engineered antibodies
- introduce veneered antibodies
- describe de-humanizing CDR-grafted antibodies
- discuss human antibodies
- motivate transgenic mammals
- describe transgenic animals with human immunoglobulin loci
- introduce Cre/Lox system
- discuss inactivated endogenous Ig loci
- describe exogenous immunoglobulin locus
- motivate hybridomas
- introduce HuMAb-MOUSE
- describe TransChromo Mouse
- discuss human antibody responses
- introduce in vitro activated B cells
- motivate antibody display libraries
- describe phage display libraries
- introduce yeast display methods
- discuss ribosome mRNA display methods
- describe microbial cell display methods
- introduce trioma technology
- describe producing human antibodies by trioma technology
- motivate in vitro immunization of human blood
- describe human peripheral blood treatment
- introduce mouse-human hybridomas
- discuss immunization of murines transformed to express human immunoglobulin genes

### VI. Other Antibody Forms.

- introduce nanobodies
- describe VHH domains
- derive VHH from camelidae heavy chain antibodies
- obtain VHH from other species
- mutate human residues to VHH resembling residues
- produce camelized human VH domains
- derive libraries of single VH domains
- express VH domains in E. coli
- define dAbs
- describe dAb binding to antigen
- clone and screen immunoglobulin sequences
- construct multivalent polypeptides
- produce VHH/nanobodies
- cite references for VHH/nanobody production
- introduce UniBodies
- describe UniBody production
- cite reference for UniBody production
- introduce Affibodies
- describe Affibody production
- cite reference for Affibody production
- describe phage display technology
- select affibody variants
- cite reference for affibody production
- describe methods of producing affibodies
- cite reference for affibody production
- summarize affibody production

### VII. Assaying for Neutralizing Activity of Anti-BoNT Antibodies

- introduce in vivo neutralization measurements
- describe in vitro hemidiaphragm preparation assay
- incubate antibodies with BoNT
- measure twitch tension reduction

### VIII. Diagnostic Assays.

- introduce diagnostic assays for BoNT toxin detection
- explain detection and quantification of BoNT in biological samples
- describe biological samples derived from patients
- list preferred biological samples
- mention sample isolation methods
- describe sample pretreatment methods
- introduce immunological binding assays
- define immunoassay
- describe BoNT polypeptide detection using anti-BoNT antibodies
- list examples of immunological binding assays
- describe labeling agents for immunoassays
- explain antibody labeling
- introduce non-competitive assay formats
- describe sandwich assay
- explain indirect labeling
- introduce competitive assay formats
- describe competitive assay using added BoNT/E
- explain measurement of BoNT/E bound to anti-BoNT/E antibody
- introduce reduction of non-specific binding
- describe proteinaceous composition coating
- introduce substrates for immobilizing biomolecules
- list examples of solid surfaces
- describe covalent bonding methods
- explain non-covalent binding methods
- introduce other assay formats
- describe analytic biochemical methods
- list examples of immunological methods
- introduce Western blot analysis
- describe liposome immunoassays
- introduce labeling of anti-BoNT antibodies
- describe labeling methods
- list examples of detectable labels
- explain indirect labeling methods
- describe conjugation of labels to signal generating compounds
- list examples of signal generating compounds
- describe means of detecting labels

### IX. Compositions.

- introduce BoNT-neutralizing antibodies
- describe pharmaceutical composition
- motivate high affinity antibodies
- describe neutralization of BoNT subtypes
- list exemplary antibodies
- describe composition with multiple antibodies
- motivate potency increase
- describe epitope recognition
- contemplate compositions with multiple antibodies
- list additional antibodies
- describe exemplary composition for BoNT/B
- describe optional substitutions
- describe exemplary composition for BoNT/E
- describe optional substitutions
- contemplate compositions for multiple serotypes
- describe antibodies for BoNT/A
- describe exemplary composition for multiple serotypes
- describe optional substitutions
- describe pharmaceutical administration
- describe oral administration
- describe protection from digestion
- describe parenteral administration
- describe aqueous carriers
- describe non-aqueous carriers
- describe antihydration agents
- describe concentration of antihydration agents
- describe sterilization and auxiliary substances
- describe dosage and administration

## EXAMPLES

- provide illustrative examples

### Example 1

- introduce human monoclonal antibodies to botulinum neurotoxin types A and B
- describe methods and materials used
- list oligonucleotide primers used
- describe primary library construction
- describe light chain shuffled library construction
- describe VH gene amplification from pYD2
- list other primers used
- describe strains, media, antibodies, and toxins used
- describe yeast strain maintenance
- describe scFv yeast surface display induction
- describe immune scFv yeast antibody library generation
- describe blood sample collection and PBL isolation
- describe total RNA isolation and cDNA synthesis
- describe VH and VK gene fragment amplification
- describe scFv linker DNA template preparation
- describe scFv gene repertoire construction
- describe scFv gene ligation into pYD2 vector
- describe selection and characterization of lead BoNT/B and BoNT/A scFv antibodies
- describe antibody selection and sorting process
- describe construction and expression of yeast displayed BoNT/B domains
- describe mapping of antibody binding to yeast displayed BoNT/B domains
- describe mapping the overlap of BoNT antibodies
- create light chain library
- amplify VK gene fragments
- append scFv linker to VL genes
- clone VL genes into pYD2
- create light chain shuffled scFv libraries
- amplify VH gene
- clone VH gene into pYD2
- create chain shuffled libraries
- sort libraries on BoNT/A1 or BoNT/B1
- identify highest affinity clone
- measure KD of yeast displayed scFv
- convert scFv to IgG
- establish stable CHO DG44 cell lines
- purify IgG from cell culture supernatant
- determine monovalent KD of IgG
- generate human yeast displayed scFv antibody libraries
- construct scFv gene repertoires
- clone scFv gene repertoires into pYD2
- display scFv on yeast surface
- sort yeast displayed scFv libraries
- screen for antigen binding clones
- characterize scFv with respect to diversity
- measure equilibrium binding constant
- determine BoNT/B subtype specificity
- determine BoNT/B functional domain
- determine non-overlapping epitopes
- generate antibodies to Type A Botulinum Neurotoxins
- sort yeast displayed scFv libraries on BoNT/A
- identify yeast displayed scFv
- characterize scFv with respect to epitope recognition
- determine whether epitopes recognized by antibodies overlap
- perform affinity maturation of antibodies
- recombine scFv VH gene with library of VL genes
- create light chain shuffled scFv libraries
- sort libraries on BoNT/A1 or BoNT/B1
- discuss results

### Example 2

- introduce affinity maturation of human botulinum neurotoxin antibodies
- describe methods and materials used
- list oligonucleotide primers used
- describe yeast strains and media used
- describe antibodies and toxins used
- construct light chain repertoire in YVH10 for light chain shuffling
- describe two methods for constructing Fab libraries
- describe error-prone PCR for mutated VH repertoire
- clone VH gene into pPNL20S vector
- transform JAR300 yeast with pPNL20S vector
- select transformants on SD-CAA media
- construct VL libraries using conventional methods
- transform YVH10 yeast with pPNL30S vector
- select transformants on SD-CAA media
- perform yeast mating
- select diploid yeast on SD-CAA media
- induce Fab surface display
- check Fab expression using anti-SV5 antibody
- perform FACS sorting of mutant clones
- describe FACS sorting procedure
- use different subtypes of BoNT/A or B for sorting
- describe incubation times and volumes for sorting
- analyze sorted clones by BstNI fingerprinting and sequencing
- express and purify IgG from Fab genes
- describe IgG purification procedure
- measure IgG solution equilibrium binding constants
- describe flow fluorimetry procedure
- select antibodies for affinity maturation by light chain shuffling
- describe generation of BoNT Fab from scFv by yeast mating
- generate and sort Fab chain shuffled libraries
- analyze sorted clones by sequencing and FACS
- characterize chain shuffled Fab
- measure affinities of yeast displayed Fab
- compare affinities of Fab and scFv
- generate and characterize IgG constructed from Fab V-genes
- express and purify IgG from CHO cell lines
- measure solution KD for BoNT/A or BoNT/B subtypes
- compare affinities of IgG and Fab
- summarize results of affinity maturation

### Example 3

- introduce neutralization of BoNT/B in vivo by BoNT/B antibody combinations
- describe in vivo neutralization experiments
- analyze results of neutralization experiments
- discuss implications of results for therapeutic applications

### Example 4

- neutralize BoNT/E in vivo
- demonstrate potency of mAb combinations

### Example 5

- describe oligonucleotide primers
- specify primers for amplifying and cloning target antigen gene
- list strains, media, and reagents
- describe specificity and crossreactivity test
- measure yeast-displayed scFv affinity for BoNToxin
- perform binding domain test
- construct yeast-displayed BoNToxins fragments
- describe construction of yeast-displayed BoNToxins fragments
- generate IgG from scFv
- perform epitope sharing test
- analyze toxin sequences
- perform protein sequence alignment
- locate areas with antigen differences
- test by alanine scanning
- identify epitope
- measure affinity of Fab fragments for yeast displayed wild type and alanine mutants toxin domains
- calculate change in free energy of binding to wild type and alanine mutants
- describe use of Fab fragments
- eliminate avidity effect
- indicate position of functional epitope
- describe numbering system for toxin residues
- highlight residues with important contributions
- describe elimination of residues leading to loss of binding
- incorporate publications, patents, and patent applications by reference
- describe scope of invention
- indicate that various changes in form and details may be made without departing from the scope of the invention

